image: Dr. Benjamin Besse of Gustave Roussy
Credit: Dr. Benjamin Besse of Gustave Roussy
(San Diego, Calif.--September 10, 2024, 10:35 a.m. PCT) A phase 3 study comparing tusamitamab ravtansine with docetaxel in patients with advanced non-squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and immunotherapy (in combination or sequential), whose tumors highly expressed CEACAM5, is presented today at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer in San Diego, Calf., by Dr. Benjamin Besse of Gustave Roussy, in Paris, France. As previously announced by Sanofi in December 2023, the study results did not meet its primary endpoint of improved progression-free survival (PFS).
Tusamitamab ravtansine is an immunoconjugate consisting of anti-carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) conjugated to a cytotoxic agent, with antineoplastic activity.
The CARMEN-LC03 is a phase 3 open-label, randomized, pivotal, multicenter study evaluating tusamitamab ravtansine (a CEACAM5-directed antibody-drug conjugate (ADC) with cytotoxic payload DM4/ravtansine) versus docetaxel in patients with advanced non-squamous NSCLC previously treated with platinum-based chemotherapy and immunotherapy (in combination or sequential), whose tumors highly expressed CEACAM5. Dr. Besse reported the results from the prespecified final progression-free survival and first interim overall survival (OS) analyses.
The trial randomized adult patients 1:1 to intravenously receive either 100 mg/ m2 tusamitamab ravtansine once every 2 weeks or docetaxel 75 mg/m2 once every 3 weeks. Patients with CEACAM5 positivity (assessed by immunohistochemistry) of greater than or equal to 2+intensity involving ≥50% of tumor cells were included in the study. CEACAM5 is a member of the CEACAM family of 12 glycoproteins and may drive cell adhesion and migration, as well as inhibit apoptosis, and may be overexpressed in many different cancer types.
Dual primary endpoints were PFS and OS. Secondary endpoints were objective response rate (ORR), health-related quality of life (HRQoL), duration of response and safety.
Besse and colleagues randomized 194 patients to receive tusamitamab ravtansine (all patients received treatment) and 195 to docetaxel of whom 177 received treatment. 61 patients (n=36 tusamitamab ravtansine and n=25 docetaxel) remained on treatment. Most patients received 1 or 2 prior lines of therapy, had a median age of 64 years and the majority were males (59.6%). Median follow-up was 7.4 and 18.1 months for PFS (by Independent Radiologic Committee [IRC]) and OS, respectively.
According to data presented by Dr. Besse, results include:
- Median progression-free survival as per IRC for tusamitamab ravtansine and docetaxel was 5.4 vs 5.9 months, respectively (hazard ratio [HR]: 1.14; 95% confidence interval [CI]: 0.86-1.51; p=0.820).
- Median overall survival (60% Information Fraction) of tusamitamab ravtansine vs docetaxel was 12.8 vs 11.5 months; HR=0.85 (95% CI [0.64-1.11]; p=0.112).
- Similar overall response rate was observed with tusamitamab ravtansine and docetaxel. Time to deterioration of disease related symptoms/physical functioning/role functioning were numerically prolonged with tusamitamab ravtansine.
- Grade ≥ 3 treatment-related adverse events and treatment-related serious AEs, TEAE leading to discontinuation and dose reduction were lower with tusamitamab ravtansine; however, dose delay was more frequently required for tusamitamab ravtansine, mainly due to corneal events.
“Despite trends favoring tusamitamab ravtansine on interim overall survival and electronic patient reported outcomes analysis, CARMEN did not meet its co-primary endpoint of improving PFS. The higher median PFS and OS observed with docetaxel was unexpected,” said Dr. Besse. He noted that tusamitamab ravtansine showed better safety data in various important clinical categories.
These exploratory analyses identify patients with advanced non-squamous NSCLC previously treated with immunotherapy and chemotherapy who are likely to derive clinical benefit from CEACAM5-directed therapy and suggest a previously unknown prognostic role for CEACAM5 in NSCLC, Additional research would be needed to corroborate these findings.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
About the WCLC:
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2024.iaslc.org.